Rapid testing programme for fortified foods
Summary by AI BETAClose X
8 June 2026
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Aptamer initiates rapid testing programme for fortified foods
Collaboration with Imperial College London to translate Aptamer's folic acid Optimers into rapid testing kit for monitoring food fortification
Programme supported by the Gates Foundation
Aptamer Group plc (AIM: APTA), the developer of next‑generation synthetic binders for the life sciences industry, is pleased to announce a new funded research programme with Imperial College London, supported by the Gates Foundation.
Aptamer has contracted an upfront fee to develop field-compatible sample preparation and extraction methods using its existing folic acid Optimer® binders, and to supply those binders to the Güder Research Group in the Department of Bioengineering at Imperial College London for incorporation into lateral flow devices.
Aptamer has proposed a further commercial licence fee upon successful field validation of the assay, enabling the programme to provide these lateral flow devices globally. Beyond this, Aptamer anticipates additional commercial value through an ongoing supply of Optimer® materials for device manufacture.
Folic acid deficiency is a leading preventable cause of serious birth defects, such as Spina Bifida. Many lower-income countries rely on food fortification programmes as a primary public health intervention. However, no rapid test kits currently exist for measuring folate levels in fortified foods at the point of production. This programme aims to address that unmet need, developing an affordable, field-deployable solution capable of operating without cold chain infrastructure or specialist equipment in the food processing facilities where fortification takes place.
The programme will investigate the suitability of Aptamer's existing proprietary Optimer® binders for folic acid to develop an affordable, field-deployable lateral flow test for monitoring folate levels in fortified foods in developing countries, with potential for commercial application of Aptamer's existing intellectual property.
Aptamer expects to complete its in-house validation work in July 2026, at which point validated Optimer® binders will be transferred to Imperial College London. Imperial College London will then lead the incorporation of the validated binders into lateral flow tests, with field-based validation anticipated by the end of 2026.
Aptamer will supply Optimer® material throughout the development phase and potential ongoing supply to support ongoing device manufacture following successful field deployment. Aptamer retains full ownership of its Optimer® IP with no rights ceded.
Dr Arron Tolley, Chief Executive Officer of Aptamer Group, commented: "We look forward to collaborating with Imperial College London and the Gates Foundation on this critical initiative. Our Optimer® technology offers a powerful tool for improving food quality monitoring in resource-limited settings. Together, we aim to deliver a practical solution that can have a meaningful impact on maternal and child health worldwide".
- Ends -
For further information, please contact:
|
Aptamer Group plc Dr Arron Tolley, Chief Executive Officer |
+44 (0) 1904 217 404 |
|
SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Dillon Wall |
+44 (0) 20 3368 3550 |
|
Turner Pope Investments (TPI) Limited - Broker Andrew Thacker / Guy McDougall |
+44 (0) 20 3657 0050 |
|
Northstar Communications Limited - Investor Relations Sarah Hollins |
+44 (0) 113 730 3896 |
About Aptamer Group
Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.
Aptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.
Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.
To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund